{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:45:30Z","timestamp":1790649930608,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jdiacomp.2020.107703","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T03:23:59Z","timestamp":1596165839000},"page":"107703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis"],"prefix":"10.1016","volume":"34","author":[{"given":"Shintaro","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Jojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshie","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tomaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Aso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2020.107703_bb0005","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.2741\/2285","article-title":"Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis","volume":"12","author":"Aso","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0010","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2337\/dc12-0638","article-title":"PAI-1 and diabetes: a journey from the bench to the bedside","volume":"35","author":"Schneider","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-017-0515-9","article-title":"Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk","volume":"16","author":"Kearney","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0020","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1538-7836.2005.01420.x","article-title":"PAI-1 and atherothrombosis","volume":"3","author":"Vaughan","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0025","doi-asserted-by":"crossref","first-page":"860","DOI":"10.2337\/diab.46.5.860","article-title":"Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease","volume":"46","author":"Alessi","year":"1997","journal-title":"Diabetes."},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.28776","article-title":"NASH Clinical Research Network Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease","volume":"65","author":"Ajmera","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0035","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/meta.2002.31334","article-title":"Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1","volume":"51","author":"Aso","year":"2002","journal-title":"Metabolism."},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0040","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","article-title":"SGLT inhibitors in management of diabetes","volume":"1","author":"Tahrani","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0045","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0055","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0060","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2337\/db05-1525","article-title":"Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin","volume":"55","author":"Aso","year":"2006","journal-title":"Diabetes."},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0065","doi-asserted-by":"crossref","first-page":"E350","DOI":"10.1002\/oby.20300","article-title":"Early changes of abdominal adiposity detected with weekly dual bioelectrical impedance analysis during calorie restriction","volume":"21","author":"Ida","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0070","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1210\/jcem.86.2.7410","article-title":"Framingham Heart Study. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance","volume":"86","author":"Hadigan","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0075","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/ATVBAHA.117.309451","article-title":"Plasminogen activator inhibitor-1 is a marker and a mediator of senescence","volume":"37","author":"Vaughan","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-018-0166-4","article-title":"Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"Jung","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1096-9136(199601)13:1<59::AID-DIA2>3.0.CO;2-Z","article-title":"Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians","volume":"13","author":"Nagi","year":"1996","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0090","doi-asserted-by":"crossref","first-page":"17714","DOI":"10.1038\/srep17714","article-title":"Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies","volume":"6","author":"Yarmolinsky","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40268-016-0137-9","article-title":"Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients","volume":"16","author":"Okamoto","year":"2016","journal-title":"Drugs R D"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0105","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1046\/j.1365-2141.1996.416951.x","article-title":"Development and clinical application of a new ELISA assay to determine plasmin-alpha2-antiplasmin complexes in plasma","volume":"92","author":"Montes","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2141.1988.tb02490.x","article-title":"Plasminogen activator inhibitor (PAI-1) in plasma and platelets","volume":"70","author":"Booth","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0115","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/diacare.28.9.2211","volume":"28","author":"Aso","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0120","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1007\/s00125-005-1938-5","article-title":"Finnish Diabetes Prevention Study Group Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study","volume":"48","author":"H\u00e4m\u00e4l\u00e4inen","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0125","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0130","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cvr\/cvx086","article-title":"New insights into the role of adipose tissue in thrombosis","volume":"113","author":"Vilahur","year":"2017","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0135","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s13300-017-0274-3","article-title":"Efficacy of additional canagliflozin administration to type 2 diabetes patients receiving insulin therapy: examination of diurnal glycemic patterns using continuous glucose monitoring (CGM)","volume":"8","author":"Matsumura","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism."},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0145","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s11695-014-1484-7","article-title":"Roux-en-Y gastric bypass decreases pro-inflammatory and thrombotic biomarkers in individuals with extreme obesity","volume":"25","author":"Netto","year":"2015","journal-title":"Obes Surg"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0150","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JOE-14-0405","article-title":"20 years of leptin: leptin at 20: an overview","volume":"223","author":"Friedman","year":"2014","journal-title":"J Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0155","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1016\/j.amjmed.2003.08.014","article-title":"Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease","volume":"115","author":"Lyon","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/5584_2019_382","article-title":"Influence of glycemic control on coagulation and lipid metabolism in pregnancies complicated by pregestational and gestational diabetes mellitus","volume":"1176","author":"Teliga-Czajkowska","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0165","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2020.107703_bb0175","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(20)30038-3","article-title":"Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials","volume":"8","author":"Ghosh-Swaby","year":"2020","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872720304712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872720304712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:11:05Z","timestamp":1761005465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872720304712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1056872720304712"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107703","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107703"}}